Combined Exenatide and Dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with Metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial
Radiotherapy increases tumor cell ferroptosis susceptibility, significantly inducing the expression of long-chain acyl-CoA synthetase 4 (ACSL4) and the ferroptosis inhibitors SLC7A11 and GPX4, thereby effectively suppressing tumor growth (109)
Infectious agents Extensive efforts have been made, with limited success, to establish an infectious agent as the cause of IC
Wegovy/semaglutide works only on the GLP-1 receptor, whereas Zepbound/tirzepatide acts on both GLP-1 and GIP receptors
As of late 2025, it is not yet FDA-approved
[140] reportedthat recombinant IL-35 suppressed the Th17 response in AR patients through the MEK and JNK pathways